Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based 4SC has reported that its Phase II Saphire trial evaluating resminostat in patients suffering from relapsed/refractory Hodgkin's Lymphoma (HL) has shown safety, tolerability and anti-tumour activity.
Subscribe to our email newsletter
The results of the trial demonstrated that Resminostat monotherapy showed substantial anti-tumour activity, including complete and partial tumour responses.
Furthermore, the study demonstrated that the drug was safe and well tolerated in the advanced stage patient population.
The overall response rate (ORR) of 33.3% together with the clinical benefit recorded in total for 54.5% of the patients shows the substantial anti-tumour activity of resminostat monotherapy in an advanced and heavily pre-treated Hodgkin’s Lymphoma patient population.